Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

The attention-enhancing effects of spearmint extract supplementation in healthy men and women: a randomized, double-blind, placebo-controlled, parallel trial.

Falcone PH, Nieman KM, Tribby AC, Vogel RM, Joy JM, Moon JR, Slayton CA, Henigman MM, Lasrado JA, Lewis BJ, Fonseca BA, Herrlinger KA.

Nutr Res. 2019 Apr;64:24-38. doi: 10.1016/j.nutres.2018.11.012. Epub 2018 Dec 7.

2.

Efficacy of a nootropic spearmint extract on reactive agility: a randomized, double-blind, placebo-controlled, parallel trial.

Falcone PH, Tribby AC, Vogel RM, Joy JM, Moon JR, Slayton CA, Henigman MM, Lasrado JA, Lewis BJ, Fonseca BA, Nieman KM, Herrlinger KA.

J Int Soc Sports Nutr. 2018 Dec 12;15(1):58. doi: 10.1186/s12970-018-0264-5.

3.

Resistance Exercise Selectively Mobilizes Monocyte Subsets: Role of Polyphenols.

Jajtner AR, Townsend JR, Beyer KS, Varanoske AN, Church DD, Oliveira LP, Herrlinger KA, Radom-Aizik S, Fukuda DH, Stout JR, Hoffman JR.

Med Sci Sports Exerc. 2018 Nov;50(11):2231-2241. doi: 10.1249/MSS.0000000000001703.

PMID:
29957728
4.

Polyphenol supplementation alters intramuscular apoptotic signaling following acute resistance exercise.

Townsend JR, Stout JR, Jajtner AR, Church DD, Beyer KS, Riffe JJ, Muddle TWD, Herrlinger KL, Fukuda DH, Hoffman JR.

Physiol Rep. 2018 Jan;6(2). doi: 10.14814/phy2.13552.

5.

Spearmint Extract Improves Working Memory in Men and Women with Age-Associated Memory Impairment.

Herrlinger KA, Nieman KM, Sanoshy KD, Fonseca BA, Lasrado JA, Schild AL, Maki KC, Wesnes KA, Ceddia MA.

J Altern Complement Med. 2018 Jan;24(1):37-47. doi: 10.1089/acm.2016.0379. Epub 2018 Jan 9.

6.

Impact of Polyphenol Supplementation on Acute and Chronic Response to Resistance Training.

Beyer KS, Stout JR, Fukuda DH, Jajtner AR, Townsend JR, Church DD, Wang R, Riffe JJ, Muddle TWD, Herrlinger KA, Hoffman JR.

J Strength Cond Res. 2017 Nov;31(11):2945-2954. doi: 10.1519/JSC.0000000000002104.

7.

Volume and Quality in Visceral Medicine.

Herrlinger KR, Keck T.

Visc Med. 2017 May;33(2):104-105. doi: 10.1159/000470894. Epub 2017 Apr 13. No abstract available.

8.

Safety and tolerability of a dried aqueous spearmint extract.

Lasrado JA, Nieman KM, Fonseca BA, Sanoshy KD, Schild AL, Herrlinger KA.

Regul Toxicol Pharmacol. 2017 Jun;86:167-176. doi: 10.1016/j.yrtph.2017.03.005. Epub 2017 Mar 7.

PMID:
28286189
9.

The effect of polyphenols on cytokine and granulocyte response to resistance exercise.

Jajtner AR, Hoffman JR, Townsend JR, Beyer KS, Varanoske AN, Church DD, Oliveira LP, Herrlinger KA, Radom-Aizik S, Fukuda DH, Stout JR.

Physiol Rep. 2016 Dec;4(24). pii: e13058. doi: 10.14814/phy2.13058.

10.

Phytochemical Profiling of Flavonoids, Phenolic Acids, Terpenoids, and Volatile Fraction of a Rosemary (Rosmarinus officinalis L.) Extract.

Mena P, Cirlini M, Tassotti M, Herrlinger KA, Dall'Asta C, Del Rio D.

Molecules. 2016 Nov 19;21(11). pii: E1576.

11.

Phenolic and Volatile Composition of a Dry Spearmint (Mentha spicata L.) Extract.

Cirlini M, Mena P, Tassotti M, Herrlinger KA, Nieman KM, Dall'Asta C, Del Rio D.

Molecules. 2016 Aug 3;21(8). pii: E1007. doi: 10.3390/molecules21081007.

12.

Effect of botanical extracts containing carnosic acid or rosmarinic acid on learning and memory in SAMP8 mice.

Farr SA, Niehoff ML, Ceddia MA, Herrlinger KA, Lewis BJ, Feng S, Welleford A, Butterfield DA, Morley JE.

Physiol Behav. 2016 Oct 15;165:328-38. doi: 10.1016/j.physbeh.2016.08.013. Epub 2016 Aug 12.

13.

In Reply.

Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF.

Dtsch Arztebl Int. 2016 Jul 1;113(26):462. doi: 10.3238/arztebl.2016.0462b. No abstract available.

14.

Inflammatory Bowel Disease.

Wehkamp J, Götz M, Herrlinger K, Steurer W, Stange EF.

Dtsch Arztebl Int. 2016 Feb 5;113(5):72-82. doi: 10.3238/arztebl.2016.0072. Review.

15.

Supplementation with a polyphenolic blend improves post-exercise strength recovery and muscle soreness.

Herrlinger KA, Chirouzes DM, Ceddia MA.

Food Nutr Res. 2015 Dec 18;59:30034. doi: 10.3402/fnr.v59.30034. eCollection 2015.

16.

Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues.

Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, Herrlinger KR, Fellermann K, Büning J.

J Crohns Colitis. 2016 Jan;10(1):31-7. doi: 10.1093/ecco-jcc/jjv175. Epub 2015 Sep 28.

PMID:
26419459
17.

[Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations (Spanish version)].

van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO.

Rev Gastroenterol Mex. 2015 Jan-Mar;80(1):74-106. doi: 10.1016/j.rgmx.2014.10.008. Epub 2015 Mar 11. Spanish. No abstract available.

18.

The safety of a dry spearmint extract in vitro and in vivo.

Lasrado JA, Trinker D, Ceddia MA, Herrlinger KA.

Regul Toxicol Pharmacol. 2015 Mar;71(2):213-24. doi: 10.1016/j.yrtph.2014.12.007. Epub 2014 Dec 16.

PMID:
25527048
19.

[Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease" 2014].

Preiß JC, Bokemeyer B, Buhr HJ, Dignaß A, Häuser W, Hartmann F, Herrlinger KR, Kaltz B, Kienle P, Kruis W, Kucharzik T, Langhorst J, Schreiber S, Siegmund B, Stallmach A, Stange EF, Stein J, Hoffmann JC; German Society of Gastroenterology.

Z Gastroenterol. 2014 Dec;52(12):1431-84. doi: 10.1055/s-0034-1385199. Epub 2014 Dec 4. German. No abstract available.

PMID:
25474283
20.

[Azathioprine in Crohn's disease therapy--guidance against the background of recent studies].

Schmidt C, Herrlinger K, Siegmund B, Bokemeyer B, Schreiber S, Stallmach A; Kompetenznetz Darmerkrankungen.

Z Gastroenterol. 2014 Dec;52(12):1423-30. doi: 10.1055/s-0034-1385650. Epub 2014 Dec 4. Review. German.

PMID:
25474282
21.

[Therapy of chronic inflammatory bowel diseases. Standards, controversies and perspectives].

Herrlinger K, Fellermann K, Stange EF.

Internist (Berl). 2014 Aug;55(8):906-17. doi: 10.1007/s00108-013-3442-1. Review. German.

PMID:
25030498
22.

A green and black tea extract benefits urological health in men with lower urinary tract symptoms.

Katz A, Efros M, Kaminetsky J, Herrlinger K, Chirouzes D, Ceddia M.

Ther Adv Urol. 2014 Jun;6(3):89-96. doi: 10.1177/1756287214526924.

23.

[Inflammatory bowel disease: an overview].

Herrlinger K.

Med Monatsschr Pharm. 2013 Nov;36(11):402-8; quiz 409. Review. German.

PMID:
24640117
24.

Therapeutic peptides in inflammatory bowel disease.

Herrlinger KR, Stange EF, Fellermann K.

Expert Opin Biol Ther. 2014 Apr;14(4):455-66. doi: 10.1517/14712598.2014.880109. Review.

PMID:
24450849
25.

The debated role for thiopurines in Crohn's disease.

Herrlinger KR, Stange EF.

J Crohns Colitis. 2014 Feb;8(2):172-4. doi: 10.1016/j.crohns.2013.11.026. Epub 2013 Dec 15.

PMID:
24342765
26.

Differences between treatment guidelines--Germany.

Herrlinger KR.

Dig Dis. 2013;31(3-4):357-9. doi: 10.1159/000354694. Epub 2013 Nov 14. Review.

PMID:
24246987
27.

Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels.

Angelberger S, Schaeffeler E, Teml A, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR, Schwab M, Reinisch W.

Inflamm Bowel Dis. 2013 Mar;19(3):590-8. doi: 10.1097/MIB.0b013e31827eea8b.

PMID:
23388543
28.

Antihypertensive effect of passion fruit peel extract and its major bioactive components following acute supplementation in spontaneously hypertensive rats.

Lewis BJ, Herrlinger KA, Craig TA, Mehring-Franklin CE, Defreitas Z, Hinojosa-Laborde C.

J Nutr Biochem. 2013 Jul;24(7):1359-66. doi: 10.1016/j.jnutbio.2012.11.003. Epub 2013 Jan 17.

PMID:
23333089
29.

Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients.

Schmidt KJ, Herrlinger KR, Emmrich J, Barthel D, Koc H, Lehnert H, Stange EF, Fellermann K, Büning J.

Aliment Pharmacol Ther. 2013 Jan;37(1):129-36. doi: 10.1111/apt.12118. Epub 2012 Nov 5.

30.

Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.

Herrlinger KR, Diculescu M, Fellermann K, Hartmann H, Howaldt S, Nikolov R, Petrov A, Reindl W, Otte JM, Stoynov S, Strauch U, Sturm A, Voiosu R, Ammendola A, Dietrich B, Hentsch B, Stange EF.

J Crohns Colitis. 2013 Sep;7(8):636-43. doi: 10.1016/j.crohns.2012.09.016. Epub 2012 Oct 16.

PMID:
23078909
31.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations.

Van Assche G, Dignass A, Bokemeyer B, Danese S, Gionchetti P, Moser G, Beaugerie L, Gomollón F, Häuser W, Herrlinger K, Oldenburg B, Panes J, Portela F, Rogler G, Stein J, Tilg H, Travis S, Lindsay JO; European Crohn's and Colitis Organisation.

J Crohns Colitis. 2013 Feb;7(1):1-33. doi: 10.1016/j.crohns.2012.09.005. Epub 2012 Oct 3. No abstract available.

32.

[Histoplasmosis: uncommon opportunistic infection in a patient with HIV infection].

Escher M, Kainikkara TM, Grabner A, Ott G, Stange EF, Herrlinger KR.

Dtsch Med Wochenschr. 2012 Feb;137(6):260-4. doi: 10.1055/s-0031-1298872. Epub 2012 Jan 31. German.

PMID:
22294110
33.

[Biologicals first-line in chronic inflammatory bowel disease? No].

Herrlinger K, Stange EF.

Dtsch Med Wochenschr. 2011 Sep;136(36):1789. doi: 10.1055/s-0031-1286103. Epub 2011 Aug 31. German. No abstract available.

PMID:
21882135
34.

[Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011].

Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, Barretton G, Bokemeyer B, Fichtner-Feigl S, Hagel S, Herrlinger KR, Jantschek G, Kroesen A, Kruis W, Kucharzik T, Langhorst J, Reinshagen M, Rogler G, Schleiermacher D, Schmidt C, Schreiber S, Schulze H, Stange E, Zeitz M, Hoffmann JC, Stallmach A.

Z Gastroenterol. 2011 Sep;49(9):1276-341. doi: 10.1055/s-0031-1281666. Epub 2011 Aug 24. German. No abstract available.

PMID:
21866493
35.

[Ulcerative colitis--state of the art in diagnosis and therapeutic strategies].

Herrlinger K.

MMW Fortschr Med. 2011 Jun 9;153(23):75-8; quiz 79. Review. German. No abstract available.

PMID:
21688500
36.

ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitis.

Herrlinger KR, Koc H, Winter S, Teml A, Stange EF, Fellermann K, Fritz P, Schwab M, Schaeffeler E.

Clin Pharmacol Ther. 2011 Mar;89(3):422-8. doi: 10.1038/clpt.2010.348. Epub 2011 Feb 2.

PMID:
21289623
37.

Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis--a need for prophylaxis.

Escher M, Stange EF, Herrlinger KR.

J Crohns Colitis. 2010 Nov;4(5):606-9. doi: 10.1016/j.crohns.2010.05.004. Epub 2010 Jun 15.

PMID:
21122569
38.

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.

Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, Lindsay J; European Crohn's and Colitis Organisation (ECCO).

J Crohns Colitis. 2010 Feb;4(1):63-101. doi: 10.1016/j.crohns.2009.09.009. Epub 2009 Dec 21. No abstract available.

39.

Infliximab, azathioprine, or combination therapy for Crohn's disease.

Herrlinger KR, Stange EF.

N Engl J Med. 2010 Sep 9;363(11):1086; author reply 1087-8. doi: 10.1056/NEJMc1005805. No abstract available.

PMID:
20825325
40.

[Treatment of Crohn's disease: step-up or top-down?].

Herrlinger K, Stange EF.

Dtsch Med Wochenschr. 2010 Aug;135(34-35):1694-8. doi: 10.1055/s-0030-1262464. Epub 2010 Aug 18. Review. German. No abstract available.

PMID:
20721847
41.

[Classification and management of upper gastrointestinal bleeding].

Herrlinger K.

Internist (Berl). 2010 Sep;51(9):1145-56; quiz 1157. doi: 10.1007/s00108-010-2590-9. Review. German.

PMID:
20680239
42.

Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.

Reinisch W, Angelberger S, Petritsch W, Shonova O, Lukas M, Bar-Meir S, Teml A, Schaeffeler E, Schwab M, Dilger K, Greinwald R, Mueller R, Stange EF, Herrlinger KR; International AZT-2 Study Group.

Gut. 2010 Jun;59(6):752-9. doi: 10.1136/gut.2009.194159.

PMID:
20551460
43.

[New therapeutic approaches to special diseases of the small intestine].

Schumann M, Herrlinger K, Zeitz M, Stange EF.

Internist (Berl). 2010 Jun;51(6):730-6. doi: 10.1007/s00108-009-2568-7. German.

PMID:
20449560
44.

Determination of 6-thioguanosine diphosphate and triphosphate and nucleoside diphosphate kinase activity in erythrocytes: novel targets for thiopurine therapy?

Karner S, Shi S, Fischer C, Schaeffeler E, Neurath MF, Herrlinger KR, Hofmann U, Schwab M.

Ther Drug Monit. 2010 Apr;32(2):119-28. doi: 10.1097/FTD.0b013e3181d12f19.

PMID:
20216118
45.

Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus.

Herrlinger KR, Barthel DN, Schmidt KJ, Büning J, Barthel CS, Wehkamp J, Stange EF, Fellermann K.

Aliment Pharmacol Ther. 2010 May;31(9):1036-41. doi: 10.1111/j.1365-2036.2010.04267.x. Epub 2010 Feb 18.

46.

[Updated German S3-guideline regarding the diagnosis of Crohn's disease--implementation of radiological modalities].

Schreyer AG, Ludwig D, Koletzko S, Hoffmann JC, Preiss JC, Zeitz M, Stange E, Herrlinger KR; Deutsche Gesellschaft für Verdauungs-und Stoffwechselkrankheiten, Kompetenznetzwerks CED (Chronisch entzündliche Darmerkrankungen).

Rofo. 2010 Feb;182(2):116-21. doi: 10.1055/s-0028-1109837. Epub 2009 Oct 27. German.

PMID:
19862656
47.

[Chronic inflammatory intestinal diseases. Pathophysiology and therapy].

Herrlinger K, Wittig B, Stange EF.

Internist (Berl). 2009 Oct;50(10):1229-46; quiz 1247. doi: 10.1007/s00108-009-2485-9. Review. German.

PMID:
19777197
48.

Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease.

Kübler I, Koslowski MJ, Gersemann M, Fellermann K, Beisner J, Becker S, Rothfuss K, Herrlinger KR, Stange EF, Wehkamp J.

Aliment Pharmacol Ther. 2009 Sep 15;30(6):621-33. doi: 10.1111/j.1365-2036.2009.04070.x. Epub 2009 Jun 22.

49.

Clinical trial: cyclophosphamide pulse therapy - a promising therapeutic alternative in refractory Crohn's disease.

Schmidt KJ, Fellermann K, Wellhöner P, Weitz G, Homann N, Herrlinger K, Lehnert H, Ludwig D, Büning J.

Aliment Pharmacol Ther. 2009 Jun 15;29(12):1230-9. doi: 10.1111/j.1365-2036.2009.03999.x. Epub 2009 Mar 19.

50.

Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis.

Gersemann M, Becker S, Kübler I, Koslowski M, Wang G, Herrlinger KR, Griger J, Fritz P, Fellermann K, Schwab M, Wehkamp J, Stange EF.

Differentiation. 2009 Jan;77(1):84-94. doi: 10.1016/j.diff.2008.09.008. Epub 2008 Oct 22.

PMID:
19281767

Supplemental Content

Loading ...
Support Center